The Psychiatric Characteristics of People on a Mephedrone (“bath salts”) Binge

References

• Bajaj, N., Mullen, D., & Wylie, S. (2010). Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. Case Reports, 2010(1), bcr0220102780. doi:10.1136/bcr.02.2010.2780
   PubMedGoogle Scholar
• Becker, H. C. (2008). Alcohol dependence, withdrawal, and relapse. Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism, 31(4), 348–361.
   PubMedGoogle Scholar
• Blanco, C., Han, B., & Jones, C. M. (2018). Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. Journal of Clinical Psychiatry, 79(6), 18m12174.
   PubMed Web of Science ®Google Scholar
• Blumenthal, H., Taylor, D. J., Cloutier, R. M., Baxley, C., & Lasslett, H. (2019). The links between social anxiety disorder, insomnia symptoms, and alcohol use disorders: Findings from a large sample of adolescents in the United States. Behavior Therapy, 50(1), 50–59. doi:10.1016/j.beth.2018.03.010
   PubMed Web of Science ®Google Scholar
• Boden, J. M., & Fergusson, J. M. (2011). Alcohol and addiction. Addiction, 106(5), 906–914. doi:10.1111/j.1360-0443.2010.03351.x
   PubMed Web of Science ®Google Scholar
• Borges, G., Bagge, C. L., Cherpitel, C. J., Conner, K. R., Orozco, R., & Rossow, I. (2017). A meta-analysis of acute use of alcohol and the risk of suicide attempt. Psychological Medicine, 47(5), 949–957. doi:10.1017/S0033291716002841
   PubMed Web of Science ®Google Scholar
• Borges, G., Cherpitel, C. J., Orozco, R., Ye, Y., Monteiro, M., Hao, W., & Benegal, V. (2017). A dose-response estimate for acute alcohol use and risk of suicide attempt. Addiction Biology, 22(6), 1554–1561. doi:10.1111/adb.12439
   PubMed Web of Science ®Google Scholar
• Bossert, J. M., Ghitza, U. E., Lu, L., Epstein, D. H., & Shaham, Y. (2005). Neurobiology of relapse to heroin and cocaine seeking: An update and clinical implications. European Journal of Pharmacology, 526(1–3), 36–50. doi:10.1016/j.ejphar.2005.09.030
   PubMed Web of Science ®Google Scholar
• Brunt, T. M., Poortman, A., Niesink, R. J., & van den Brink, W. (2011). Instability of the ecstasy market and a new kid on the block: Mephedrone. Journal of Psychopharmacology, 25(11), 1543–1547. doi:10.1177/0269881110378370
   PubMed Web of Science ®Google Scholar
• Budzynska, B., Michalak, A., Frankowska, M., Kaszubska, K., & Biała, G. (2017). Acute behavioral effects of co-administration of mephedrone and MDMA in mice. Pharmacological Reports, 69(2), 199–205. doi:10.1016/j.pharep.2016.10.006
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., King, L. A., & Nutt, D. J. (2011). A web- based survey on mephedrone. Drug and Alcohol Dependence, 118(1), 19–22. doi:10.1016/j.drugalcdep.2011.02.011
   PubMed Web of Science ®Google Scholar
• Chen, V. C., Ting, H., & Wu, M. H. (2017). Sleep disturbance and its associations with severity of dependence, depression and quality of life among heroin-dependent patients: A cross-sectional descriptive study. Substance Abuse Treatment, Prevention and Policy, 12(1), 16.
   PubMedGoogle Scholar
• Ciudad-Roberts, A., Camarasa, J., Ciudad, C. J., Pubill, D., & Escubedo, E. (2015). Alcohol enhances the psychostimulant and conditioning effects of mephedrone in adolescent mice; postulation of unique roles of D3 receptors and BDNF in place preference acquisition. British Journal of Pharmacology, 172(20), 4970–4784. doi:10.1111/bph.13266
   PubMed Web of Science ®Google Scholar
• Crouse, J. J., Lee, R. S. C., White, D., Moustafa, A. A., Hickie, I. B., & Hermens, D. F. (2018). Distress and sleep quality in young amphetamine-type stimulant users with an affective or psychotic illness. Psychiatry Research, 262, 254–261. doi:10.1016/j.psychres.2018.02.033
   PubMed Web of Science ®Google Scholar
• Dargan, P. I., Albert, S., & Wood, D. M. (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM, 103(11), 875–879. doi:10.1093/qjmed/hcq134
   PubMed Web of Science ®Google Scholar
• de Sousa Fernandes Perna, E. B., Papaseit, E., Pérez-Mañá, C., Mateus, J., Theunissen, E. L., Kuypers, K. P. C., de la Torre, R., Farré, M., & Ramaekers, J. G. (2016). Neurocognitive performance following acute mephedrone administration, with and without alcohol. Journal of Psychopharmacology, 30(12), 1305–1312. doi:10.1177/0269881116662635
   PubMed Web of Science ®Google Scholar
• Dickson, A. J., Vorce, S. P., Levine, B., & Past, M. R. (2010). Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. Journal of Analytical Toxicology, 34(3), 162–168. doi:10.1093/jat/34.3.162
   PubMed Web of Science ®Google Scholar
• Dodds, T. J. (2017). Prescribed benzodiazepines and suicide risk: A review of the literature. Primary Care Companion for CNS Disorders, 19(2), 1–6.
   Google Scholar
• Dybdal-Hargreaves, N. F., Holder, N. D., Ottoson, P. E., Sweeney, M. D., & Williams, T. (2013). Mephedrone: Piublic health risk, mechanisms of action, and behavioral effects. European Journal of Pharmacology, 714(1–3), 32–40. doi:10.1016/j.ejphar.2013.05.024
   PubMed Web of Science ®Google Scholar
• Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017). Opioid addiction: Who are your real friends? Neuroscience & Biobehavioral Reviews, 83, 697–712. doi:10.1016/j.neubiorev.2017.05.017
   PubMed Web of Science ®Google Scholar
• Farrell, M. R., Schoch, H., & Mahler, S. V. (2018). Modeling cocaine relapse in rodents: Behavioral considerations and circuit mechanisms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 87, 33–47. doi:10.1016/j.pnpbp.2018.01.002
   PubMed Web of Science ®Google Scholar
• Ferreira, B., Dias da Silva, D., Carvalho, F., de Lourdes Bastos, M., & Carmo, H. (2019). The novel psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone): A review. Forensic Science International, 295, 54–63. doi:10.1016/j.forsciint.2018.11.024
   PubMed Web of Science ®Google Scholar
• Freeman, T. P., Morgan, C. J. A., Vaughn-Jones, J., Hussain, N., Karimi, K., & Curran, H. V. (2012). Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high. Addiction, 107(4), 792–800. doi:10.1111/j.1360-0443.2011.03719.x
   PubMed Web of Science ®Google Scholar
• Green, A. R., King, M. V., Shortall, S. E., & Fone, K. C. F. (2014). The preclinical pharmacology of mephedrone; not just MDMA by another name. British Journal of Pharmacology, 171(9), 2251–2268. doi:10.1111/bph.12628
   PubMed Web of Science ®Google Scholar
• Gros, D. F., Milanak, M. E., Brady, K. T., & Back, S. E. (2013). Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. The American Journal on Addictions, 22(3), 261–265. doi:10.1111/j.1521-0391.2012.12008.x
   PubMed Web of Science ®Google Scholar
• Hawton, K., Casañas I Comabella, C., Haw, C., & Saunders, K. (2013). Risk factors for suicide in individuals with depression: A systematic review. Journal of Affective Disorders, 147(1–3), 17–28. doi:10.1016/j.jad.2013.01.004
   PubMed Web of Science ®Google Scholar
• Hockenhull, J., Murphy, K. G., & Paterson, S. (2016). Mephedrone use is increasing in London. The Lancet, 387(10029), 1719–1720. doi:10.1016/S0140-6736(16)30258-6
   PubMed Web of Science ®Google Scholar
• Loi, B., Corkery, J. M., Claridge, H., Goodair, C., Chiappini, S., Gimeno Clemente, C., & Schifano, F. (2015). Deaths of individuals aged 16–24 years in the UK after using mephedrone. Human Psychopharmacology: Clinical and Experimental, 30(4), 225–232. doi:10.1002/hup.2423
   PubMed Web of Science ®Google Scholar
• Jones, L., Reed, P., & Parrott, A. (2016). Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. Journal of Psychopharmacology, 30(12), 1313–1320. doi:10.1177/0269881116653106
   PubMed Web of Science ®Google Scholar
• López-Arnau, R., Martínez-Clemente, J., Rodrigo, T., Pubill, D., Camarasa, J., & Escubedo, E. (2015). Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone. Toxicology and Applied Pharmacology, 286(1), 27–35. doi:10.1016/j.taap.2015.03.015
   PubMed Web of Science ®Google Scholar
• Lusthof, K. J., Oosting, R., Maes, A., Verschraagen, M., Dijkhuizen, A., & Sprong, A. G. A. (2011). A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Science International, 206(1–3), e93–5. doi:10.1016/j.forsciint.2010.12.014
   PubMed Web of Science ®Google Scholar
• Ma, B., Mei, D., Wang, F., Liu, Y., & Zhou, W. (2019). Cognitive enhancers as a treatment for heroin relapse and addiction. Pharmacological Research, 141, 378–383. doi:10.1016/j.phrs.2019.01.025
   PubMed Web of Science ®Google Scholar
• MacLean, R. R., Sofuoglu, M., Brede, E., Robinson, C., & Waters, A. J. (2018). Attentional bias in opioid users: A systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 270–278. doi:10.1016/j.drugalcdep.2018.07.012
   PubMed Web of Science ®Google Scholar
• Manzar, M. D., Alamri, M., Mohammed, S., Khan, M. A. Y., Chattu, V. K., Pandi-Perumal, S. R., & Bahammam, A. S. (2018). Psychometric properties of the severity of the dependence scale for Khat (SDS-Khat) in polysubstance users. BMC Psychiatry, 18(1), 343. doi:10.1186/s12888-018-1917-2
   PubMedGoogle Scholar
• Martins, S. S., Sarvet, A., Santaella-Tenorio, J., Saha, T., Grant, B. F., & Hasin, D. S. (2017). Changes in US lifetime heroin use and heroin use disorder: Prevalence from the 2001–2002 to 2012–2013. Jama Psychiatry, 74(5), 445–455. doi:10.1001/jamapsychiatry.2017.0113
   PubMed Web of Science ®Google Scholar
• Meng, H., Cao, J., Kang, J., Ying, X., Ji, J., Reynolds, W., & Rampe, D. (2012). Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicology Letters, 208(1), 62–68. doi:10.1016/j.toxlet.2011.10.010
   PubMed Web of Science ®Google Scholar
• Motbey, C. P., Hunt, G. E., Bowen, M. T., Artiss, S., & McGregor, I. S. (2012). Mephedrone (4-methylmethcathinone, ‘meow’): Acute behavioral effects and distribution of Fos expression in adolescent rats. Addiction Biology, 17(2), 409–422. doi:10.1111/j.1369-1600.2011.00384.x
   PubMed Web of Science ®Google Scholar
• Motbey, C. P., Karanges, E., Li, K. M., Wilkinson, S., Winstock, A. R., Ramsay, J., Hicks, C., Kendig, M. D., Wyatt, N., Callaghan, P. D., & McGregor, I. S. (2012). Mephedrone in adolescent rats: Residual memory impairment and acute but not lasting 5-HT depletion. PLoS One, 7(9), e45473. doi:10.1371/journal.pone.0045473
   PubMed Web of Science ®Google Scholar
• Nakajima, M., Hoffman, R., & al'Absi, M. (2017). Level of khat dependence, use patterns, and psychosocial correlates in Yemen: A cross-sectional investigation. Eastern Mediterranean Health Journal, 23(3), 161–167. doi:10.26719/2017.23.3.161
   PubMed Web of Science ®Google Scholar
• Olfson, M., Blanco, C., Wall, M., Liu, S.-M., Saha, T. D., Pickering, R. P., & Grant, B. F. (2017). National trends in suicide attempts among adults in the United States. JAMA Psychiatry, 74(11), 1095–1103. doi:10.1001/jamapsychiatry.2017.2582
   PubMed Web of Science ®Google Scholar
• Ordak, M., Nasierowski, T., & Bujalska-Zadrozny, M. (2019). The problem of mephedrone in Europe: Causes and suggested solutions. European Psychiatry, 55, 43–44. doi:10.1016/j.eurpsy.2018.09.001
   PubMedGoogle Scholar
• Ordak, M., Nasierowski, T., & Muszynska, E. (2018). The growing problem of mephedrone use in Warsaw, Poland, 2010–18. The Lancet Psychiatry, 5(10), 787. doi:10.1016/S2215-0366(18)30305-5
   PubMed Web of Science ®Google Scholar
• Pacifici, R., Zuccaro, P., Farré, M., Pichini, S., Carlo, S., Roset, P. N., Palmi, I., Ortuño, J., Menoyo, E., Segura, J., & Torre, R. (2006). Cell-mediated immune response in MDMA users after repeated dose administration: Studies in controlled versus noncontrolled settings. Annals of the New York Academy of Sciences, 965(1), 421–433. doi:10.1111/j.1749-6632.2002.tb04183.x
   Google Scholar
• Pantano, F., Tittarelli, R., Mannocchi, G., Pacifici, R., di Luca, A., Busardò, F. P., & Marinelli, E. (2017). Neurotoxicity induced by mephedrone: An up-to-date review. Current Neuropharmacology, 15(5), 738–749. doi:10.2174/1570159X14666161130130718
   PubMed Web of Science ®Google Scholar
• Papaseit, E., Moltó, J., Muga, R., Torrens, M., de la Torre, R., & Farré, M. (2017). Clinical pharmacology of the synthetic cathinone mephedrone. Current Topics in Behavioral Neurosciences, 32, 313–331. doi:10.1007/7854_2016_61
   PubMedGoogle Scholar
• Patel, N. B. (2019). Khat (Catha edulis Forsk) - And now there are three. Brain Research Bulletin, 145, 92–96. doi:10.1016/j.brainresbull.2018.07.014
   PubMed Web of Science ®Google Scholar
• Petit, A., Karila, L., Sananes, M., & Lejoyeux, M. (2013). Mephedrone: a new synthetic drug. La Presse Médicale, 42(10), 1310–1316. doi:10.1016/j.lpm.2012.11.019
   PubMed Web of Science ®Google Scholar
• Ribeiro, E., Magalhaes, T., & Dinis-Oliveira, R. J. (2012). Mephedrone, the new designer drug of abuse: Pharmacokinetics, pharmacodynamics and clinical and forensic issues. Acta Médica Portugesa, 25(2), 111–117.
   PubMed Web of Science ®Google Scholar
• Schifano, F., Oyefeso, A., Corkery, J., Cobain, K., Jambert-Gray, R., Martinotti, G., & Ghodse, A. H. (2003). Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002. Human Psychopharmacology: Clinical and Experimental, 18(7), 519–524. doi:10.1002/hup.528
   PubMed Web of Science ®Google Scholar
• Schifano, F., Albanese, A., Fergus, S., Stair, J. L., Deluca, P., Corazza, O., Davey, Z., Corkery, J., Siemann, H., Scherbaum, N., Farre’, M., Torrens, M., Demetrovics, Z., & Ghodse, A. H. (2011). Mephedrone (4-methylmethcathinone; meow meow): Chemical, pharmacological and clinical issues. Psychopharmacology, 214(3), 593–602. doi:10.1007/s00213-010-2070-x
   PubMed Web of Science ®Google Scholar
• Schifano, F., Corkery, J., & Ghodse, A. H. (2012). Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. Journal of Clinical Psychopharmacology, 32(5), 710–714. doi:10.1097/JCP.0b013e318266c70c
   PubMed Web of Science ®Google Scholar
• Seo, D., & Sinha, R. (2014). The neurobiology of alcohol craving and relapse. Handbook of Clinical Neurology, 125, 355–368. doi:10.1016/B978-0-444-62619-6.00021-5
   PubMedGoogle Scholar
• Šíchová, K., Pinterová, N., Židková, M., Horsley, R. R., Lhotková, E., Štefková, K., Vejmola, Č., Uttl, L., Balíková, M., Kuchař, M., & Páleníček, T. (2018). Mephedrone (4-Methylmethcathinone): Acute behavioral effects, hyperthermic, and pharmacokinetic profile in rats. Frontiers in Psychiatry, 8, 306. doi:10.3389/fpsyt.2017.00306
   PubMed Web of Science ®Google Scholar
• Sivanesan, E., Gitlin, N. C., & Candiotti, K. A. (2016). Opioid-induced hallucinations: A review of the literature, pathophysiology, diagnosis, and treatment. Anesthesia & Analgesia, 123(4), 836–843. doi:10.1213/ANE.0000000000001417
   PubMed Web of Science ®Google Scholar
• Spiller, H. A., Ryan, M. L., Weston, R. G., & Jansen, J. (2011). Clinical experience with analytic con rmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology, 49(6), 499–505. doi:10.3109/15563650.2011.590812
   PubMed Web of Science ®Google Scholar
• Stephane, M., Arnaout, B., & Yoon, G. (2018). Alcohol withdrawal hallucinations in the general population, an epidemiological study. Psychiatry Research, 262, 129–134. doi:10.1016/j.psychres.2018.02.021
   PubMed Web of Science ®Google Scholar
• The Council of the European Union. 2010. Council decision of 2 December 2010 on submitting 4- methylmethcathinone (mephedrone) to control measures. Official Journal of the European Union, 1–2, (2010/759/EU). http://www.emcdda.europa.eu/attachements.cfm/att_134870_EN_Council_Decision_2010_759_EU_2_December_2010.pdf.
   Google Scholar
• The Law of 10 June 2010. (2010). Amending the act on counteracting drug addiction (in Polish). Polish internet database system of legal acts. Retrieved August 28, 2010, from http://prawo.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20101430962.
   Google Scholar
• Winder, G. S., Stern, N., & Hosanagar, A. (2013). Are “bath salts” the next generation of stimulant abuse? Journal of Substance Abuse Treatment, 44(1), 42–45. doi:10.1016/j.jsat.2012.02.003
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O., & Schifano, F. (2011). Mephedrone, new kid for the chop? Addiction, 106(1), 154–161. doi:10.1111/j.1360-0443.2010.03130.x
   PubMed Web of Science ®Google Scholar
• Wood, D. M., Davies, S., Greene, S. L., Button, J., Holt, D. W., Ramsey, J., & Dargan, P. I. (2010). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology, 48(9), 924–927. doi:10.3109/15563650.2010.531021
   PubMed Web of Science ®Google Scholar
• Wood, D. M., & Dargan, P. I. (2012). Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39(2), 227–233. doi:10.1016/j.pnpbp.2012.04.020
   PubMed Web of Science ®Google Scholar
• Zawilska, J. B. (2014). Mephedrone and other cathinones. Current Opinion in Psychiatry, 27(4), 256–262. doi:10.1097/YCO.0000000000000066
   PubMed Web of Science ®Google Scholar